Cargando…

High-Dose Vitamin C in Advanced-Stage Cancer Patients

High-dose intravenously administered vitamin C (IVC) is widely used in cancer patients by complementary and alternative medicine practitioners. The most frequent indications for IVC therapy result from the belief in its effectiveness as a potent anti-cancer agent which additionally enhances chemosen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zasowska-Nowak, Anna, Nowak, Piotr Jan, Ciałkowska-Rysz, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996511/
https://www.ncbi.nlm.nih.gov/pubmed/33652579
http://dx.doi.org/10.3390/nu13030735
_version_ 1783670119081181184
author Zasowska-Nowak, Anna
Nowak, Piotr Jan
Ciałkowska-Rysz, Aleksandra
author_facet Zasowska-Nowak, Anna
Nowak, Piotr Jan
Ciałkowska-Rysz, Aleksandra
author_sort Zasowska-Nowak, Anna
collection PubMed
description High-dose intravenously administered vitamin C (IVC) is widely used in cancer patients by complementary and alternative medicine practitioners. The most frequent indications for IVC therapy result from the belief in its effectiveness as a potent anti-cancer agent which additionally enhances chemosensitivity of cancer cells and reduces chemotherapy-related toxicities and fatigue intensity. In this narrative review, we decided to deal with this issue, trying to answer the question whether there is any scientific evidence supporting the rationale for application of high-dose IVC therapy in advanced-stage cancer patients. Although results obtained from preclinical studies demonstrated that millimolar ascorbate plasma concentrations achievable only after IVC administration were cytotoxic to fast-growing malignant cells and inhibited tumor growth as well as prolonged the survival of laboratory animals, such positive effects were not found in human studies with advanced-stage cancer patients. We also have not found the rationale for the use of IVC to increase the effectiveness of chemotherapy and to reduce the chemotherapy-induced toxicity in the above mentioned group. Nevertheless, in palliative care, high-dose IVC might be considered as a therapy improving the quality of life and reducing cancer-related symptoms, such as fatigue and bone pain. However, because of the absence of placebo-controlled randomized trials on IVC efficacy in advanced-stage cancer patients, the placebo effect cannot be excluded.
format Online
Article
Text
id pubmed-7996511
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79965112021-03-27 High-Dose Vitamin C in Advanced-Stage Cancer Patients Zasowska-Nowak, Anna Nowak, Piotr Jan Ciałkowska-Rysz, Aleksandra Nutrients Review High-dose intravenously administered vitamin C (IVC) is widely used in cancer patients by complementary and alternative medicine practitioners. The most frequent indications for IVC therapy result from the belief in its effectiveness as a potent anti-cancer agent which additionally enhances chemosensitivity of cancer cells and reduces chemotherapy-related toxicities and fatigue intensity. In this narrative review, we decided to deal with this issue, trying to answer the question whether there is any scientific evidence supporting the rationale for application of high-dose IVC therapy in advanced-stage cancer patients. Although results obtained from preclinical studies demonstrated that millimolar ascorbate plasma concentrations achievable only after IVC administration were cytotoxic to fast-growing malignant cells and inhibited tumor growth as well as prolonged the survival of laboratory animals, such positive effects were not found in human studies with advanced-stage cancer patients. We also have not found the rationale for the use of IVC to increase the effectiveness of chemotherapy and to reduce the chemotherapy-induced toxicity in the above mentioned group. Nevertheless, in palliative care, high-dose IVC might be considered as a therapy improving the quality of life and reducing cancer-related symptoms, such as fatigue and bone pain. However, because of the absence of placebo-controlled randomized trials on IVC efficacy in advanced-stage cancer patients, the placebo effect cannot be excluded. MDPI 2021-02-26 /pmc/articles/PMC7996511/ /pubmed/33652579 http://dx.doi.org/10.3390/nu13030735 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
Zasowska-Nowak, Anna
Nowak, Piotr Jan
Ciałkowska-Rysz, Aleksandra
High-Dose Vitamin C in Advanced-Stage Cancer Patients
title High-Dose Vitamin C in Advanced-Stage Cancer Patients
title_full High-Dose Vitamin C in Advanced-Stage Cancer Patients
title_fullStr High-Dose Vitamin C in Advanced-Stage Cancer Patients
title_full_unstemmed High-Dose Vitamin C in Advanced-Stage Cancer Patients
title_short High-Dose Vitamin C in Advanced-Stage Cancer Patients
title_sort high-dose vitamin c in advanced-stage cancer patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996511/
https://www.ncbi.nlm.nih.gov/pubmed/33652579
http://dx.doi.org/10.3390/nu13030735
work_keys_str_mv AT zasowskanowakanna highdosevitamincinadvancedstagecancerpatients
AT nowakpiotrjan highdosevitamincinadvancedstagecancerpatients
AT ciałkowskaryszaleksandra highdosevitamincinadvancedstagecancerpatients